Global Information
회사소개 | 문의 | 비교리스트

심상성좌창 : 파이프라인 리뷰

Acne Vulgaris - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232807
페이지 정보 영문 224 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심상성좌창 : 파이프라인 리뷰 Acne Vulgaris - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 224 Pages

심상성좌창이란 얼굴 및 상구간 모낭지선소포의 비정상으로, 뾰루지가 염증을 일으켜 농포, 결절, 낭포 등이 되면 통증을 일으키는 경우도 있습니다. 청년기, 헤어젤, 유성 화장품, 헬멧 스트랩의 마찰 등 스포츠 용품, 피부 폐색 등이 소인이며 항생제로 치료합니다.

세계의 심상성좌창(Acne Vulgaris) 치료제 파이프라인에 대해 조사했으며, 현재 개발 파이프라인 상황과 최신 동향, 약제 개요, 주요 기업 및 개발중인 제품 리뷰 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

심상성좌창 개요

치료제 개발

  • 심상성좌창용 파이프라인 제품 : 개요
  • 심상성좌창 : 개발중인 치료제(기업별)
  • 심상성좌창 : 개발중인 치료제(대학·연구기관별)
  • 심상성좌창 : 개발중인 제품(기업별)
  • 심상성좌창 : 개발중인 제품(대학·연구기관별)

심상성좌창 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

심상성좌창 : 치료제 개발에 참여하고 있는 기업

  • 3SBio Inc
  • Allergan Plc
  • Almirall SA
  • Biomar Microbial Technologies
  • BioPharmX Inc
  • Braintree Laboratories Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Cell Medica Ltd
  • Cellceutix Corp
  • Celtaxsys Inc
  • Common Pharma Inc
  • Cutanea Life Sciences Inc
  • Dermira Inc
  • ELORAC Inc
  • Ensol Biosciences Inc
  • Foamix Pharmaceuticals Ltd
  • Galderma SA
  • GlaxoSmithKline Plc
  • Helix BioMedix Inc
  • Hovione FarmaCiencia SA
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Novabiotics Ltd
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phosphagenics Ltd
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Valeant Pharmaceuticals International Inc
  • Vectura Group Plc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc

약제 개요

휴지중인 프로젝트

개발 중지 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.05.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Acne Vulgaris, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Acne Vulgaris - Pipeline by Allianz Pharmascience Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Amgen Inc, H1 2020
  • Acne Vulgaris - Pipeline by AOBiome LLC, H1 2020
  • Acne Vulgaris - Pipeline by Avecho Biotechnology Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Bausch Health Companies Inc, H1 2020
  • Acne Vulgaris - Pipeline by Biomimetix JV LLC, H1 2020
  • Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2020
  • Acne Vulgaris - Pipeline by Boston Pharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2020
  • Acne Vulgaris - Pipeline by Cellix Bio Pvt Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2020
  • Acne Vulgaris - Pipeline by Daewoong Co Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Dermata Therapeutics LLC, H1 2020
  • Acne Vulgaris - Pipeline by Dermavant Sciences Inc, H1 2020
  • Acne Vulgaris - Pipeline by Devonian Health Group Inc, H1 2020
  • Acne Vulgaris - Pipeline by Eligo Bioscience SA, H1 2020
  • Acne Vulgaris - Pipeline by ELORAC Inc, H1 2020
  • Acne Vulgaris - Pipeline by Gage Development Company LLC, H1 2020
  • Acne Vulgaris - Pipeline by Galderma SA, H1 2020
  • Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2020
  • Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Johnson & Johnson, H1 2020
  • Acne Vulgaris - Pipeline by Kalytera Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Menlo Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Mimetica Pty Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Naked Biome Inc, H1 2020
  • Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Novartis AG, H1 2020
  • Acne Vulgaris - Pipeline by Origimm Biotechnology GmbH, H1 2020
  • Acne Vulgaris - Pipeline by Ortho Dermatologics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Phagelux Inc, H1 2020
  • Acne Vulgaris - Pipeline by PHI Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Photocure ASA, H1 2020
  • Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2020
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Revive Therapeutics Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Riptide Bioscience Inc, H1 2020
  • Acne Vulgaris - Pipeline by Sanotize Research And Development Corp, H1 2020
  • Acne Vulgaris - Pipeline by Sebela Pharmaceuticals Inc, H1 2020
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
  • Acne Vulgaris - Pipeline by Union Therapeutics AS, H1 2020
  • Acne Vulgaris - Pipeline by Verge Therapeutics Inc, H1 2020
  • Acne Vulgaris - Pipeline by Vyome Therapeutics Inc, H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Acne Vulgaris - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Acne Vulgaris - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Acne Vulgaris, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2020, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 20, 4, 1, 13, 6 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Acne Vulgaris - Overview
  • Acne Vulgaris - Therapeutics Development
  • Acne Vulgaris - Therapeutics Assessment
  • Acne Vulgaris - Companies Involved in Therapeutics Development
  • Acne Vulgaris - Drug Profiles
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q